Current Report Filing (8-k)
September 10 2019 - 4:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: September 6, 2019 (Date of earliest event reported)
T2 Biosystems, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36571
|
|
20-4827488
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
101 Hartwell Avenue, Lexington, Massachusetts 02421
(Address of principal executive offices and zip code)
(781) 761-4646
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.001 per share
|
|
TTOO
|
|
The Nasdaq Stock Market LLC
(Nasdaq Global Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 1.01 Entry into a Material Definitive Agreement.
On September 6, 2019, T2 Biosystems, Inc. (the Company), entered into an agreement (the BARDA Agreement) with the
Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (BARDA), which may provide up to $69 million in funding to support the further development of the Companys portfolio of
diagnostics for sepsis-causing pathogens and antibiotic-resistance genes, including a direct-from-blood panel for detection of biothreat pathogens, including threats such as B. anthracis, F. tularensis, Burkholderia spp., Y. pestis, R.
prowazekii, and toxin genes; a separate panel that is expected to cover 99% of all bloodborne bacterial infections by means of greater than 36 reported results (including detection of greater than 250 species), including pan-Gram positive and pan-Gram negative results, in addition to the bloodborne antibiotic resistant threats identified by the Centers for Disease Control and Prevention; and a
next-generation high-throughput instrument.
The BARDA Agreement is a cost-sharing contract that consists of an initial base period and
seven option periods that BARDA may exercise in its sole discretion pursuant to the BARDA Agreement, subject to the Company achieving specified milestones and deliverables. The BARDA Agreement provides for initial commitment by BARDA of an aggregate
of $6 million for the initial base period, and up to an additional $63 million if the remaining seven option periods are exercised by BARDA. Under the cost-sharing arrangement, T2 Biosystems will be responsible for a designated portion of
the costs associated with each period of work. If all option periods are exercised by BARDA, the estimated period of performance would be extended until approximately August 2024. BARDA is entitled to terminate the projects under the BARDA Agreement
for convenience at any time and is not obligated to provide continued funding beyond the base contract.
The foregoing summary is
qualified in its entirety by reference to the Agreement, a copy of which will be attached as an exhibit to the Companys Quarterly Report on Form 10-Q for the period ending September 30, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: September 10, 2019
|
|
|
|
T2 BIOSYSTEMS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John McDonough
|
|
|
|
|
|
|
John McDonough
|
|
|
|
|
|
|
CEO & President
|
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024